arXiv:2605.21301v1 Announce Type: new Abstract: In biomedical Subgroup Discovery, practitioners are interested in discovering interpretable and homogeneous subgroups within a group of patients. In this paper, assuming that healthy subjects (i.e., controls) share common but irrelevant factors of variation with the patients, we motivate and develop a Contrastive Subgroup Discovery method, entitled Deep UCSL. By contrasting patients with controls, Deep UCSL identifies subgroups driven solely by pathological factors, ignoring common variability shared with healthy subjects. Our framework employs a
The proliferation of advanced machine learning techniques, particularly in contrastive learning, is enabling more sophisticated and interpretable analyses in biomedical research.
This development allows for the discovery of more precise disease mechanisms and patient subgroups, potentially leading to highly targeted and effective therapies in healthcare.
Traditional subgroup discovery methods are enhanced by an ability to filter out common biological variability, focusing AI on disease-specific pathological factors for clearer insights.
- · Biomedical researchers
- · Pharmaceutical companies
- · Patients with complex diseases
- · AI in healthcare sector
More accurate and personalized disease classification and diagnosis in clinical settings.
Acceleration of drug discovery and development for specific patient populations, reducing trial costs and improving success rates.
Potential for a paradigm shift in medical treatment, moving from broad categories to highly individualized, 'precision medicine' approaches across many diseases.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG